REGEN Biotech
REGEN Biotech is a South Korean research-oriented biotechnology company and the development and product-company context for AestheFill. Its official history connects AestheFill to biodegradable-polymer microparticle research, clinical testing, patents, and a Korean manufacturing license.
Company reference
Section titled “Company reference”| Field | REGEN Biotech |
|---|---|
| Core Injectable Index product | AestheFill |
| Material relationship | PDLLA |
| Company orientation | Polymer and tissue-regeneration research |
| Country | South Korea |
| Product source | Official AestheFill product and safety information |
| Distribution model | Local authorized distributors and partners |
REGEN describes itself as a research-oriented bio-venture company commercializing products developed with Korean research institutions (REGEN company overview 🔗).
Product-role matrix
Section titled “Product-role matrix”| Product | Developer and product company | Manufacturing evidence | Brand | Regional approval or distribution |
|---|---|---|---|---|
| AestheFill | REGEN Biotech | REGEN’s history records a 2014 Korean manufacture license for AestheFill and PowerFill | AestheFill | Market-specific |
| PowerFill | REGEN Biotech | Included in the same Korean manufacture-license history | PowerFill | Not part of the first facial-brand set |
The matrix records the strongest currently reviewed relationship. Exact legal-manufacturer addresses, approval holders, and distributors should still come from the applicable registration or IFU.
Why REGEN matters to AestheFill interpretation
Section titled “Why REGEN matters to AestheFill interpretation”REGEN is the primary source for:
- AestheFill product identity
- PDLLA material claims
- the company’s microparticle-technology history
- product availability cautions
- authorized-distributor policy
- adverse-event reporting contact
The company page should not repeat promotional claims such as lower complication rates or superior reconstitution as settled comparative facts. Those claims need product-specific independent evidence with compatible endpoints.
Technology and evidence boundaries
Section titled “Technology and evidence boundaries”REGEN describes biodegradable polymer microparticle and scaffold technology as a core capability. AestheFill publications describe porous or microporous spherical PDLLA particles.
That relationship supports a clear product origin. It does not prove that:
- every porous PDLLA product belongs to REGEN
- the patented manufacturing concept establishes clinical superiority
- patent status equals regulatory approval
- a material patent confirms every marketed formulation
- another PDLLA product shares AestheFill’s CMC system
Selective timeline
Section titled “Selective timeline”| Date | Event | Why it changes interpretation |
|---|---|---|
| April 2000 | REGEN Biotech established | Establishes company origin |
| 2012 | Company history records AestheFill clinical tests and Korean/US microparticle patents | Connects product development with early evidence and intellectual property |
| April 2014 | Korean manufacture license recorded for AestheFill and PowerFill | Establishes a manufacturing milestone |
| May 2015 | ISO 13485 certification recorded | Adds quality-system context without replacing product approval |
| 2020 | AestheFill Taiwan launch recorded | Demonstrates regional expansion |
The dates above come from REGEN’s official history page (REGEN history 🔗). They should be treated as company-reported history and supplemented with regulator records for current approval status.
Distribution and authenticity
Section titled “Distribution and authenticity”REGEN states that it does not authorize online sales outside local official distributors (AestheFill official page 🔗). This is relevant because reseller listings often omit or distort:
- local approval status
- exact presentation
- storage and preparation
- product authenticity
- legal manufacturer and importer
Reseller availability is not evidence of regulatory availability.
Related pages
Section titled “Related pages”- Regional regulation distinguishes REGEN’s reported CE and Korean manufacturing milestones from current product approval records.
- AestheFill contains composition and preparation-evidence distinctions.
- PDLLA compares PDLLA and PDLLA + HA architectures.
- VAIM provides the closest initial Korean company comparison.
- Collagen Stimulators maps the wider company graph.